Atrium Therapeutics, Inc.
RNA
$12.69
$0.373.00%
NASDAQ
| 12/31/2025 | |||||
|---|---|---|---|---|---|
| Net Income | -153.09% | ||||
| Total Depreciation and Amortization | 110.34% | ||||
| Total Amortization of Deferred Charges | -- | ||||
| Total Other Non-Cash Items | -37.66% | ||||
| Change in Net Operating Assets | 278.38% | ||||
| Cash from Operations | -132.99% | ||||
| Capital Expenditure | -303.21% | ||||
| Sale of Property, Plant, and Equipment | -- | ||||
| Cash Acquisitions | -- | ||||
| Divestitures | -- | ||||
| Other Investing Activities | -- | ||||
| Cash from Investing | -303.21% | ||||
| Total Debt Issued | -- | ||||
| Total Debt Repaid | -- | ||||
| Issuance of Common Stock | -- | ||||
| Repurchase of Common Stock | -- | ||||
| Issuance of Preferred Stock | -- | ||||
| Repurchase of Preferred Stock | -- | ||||
| Total Dividends Paid | -- | ||||
| Other Financing Activities | 137.37% | ||||
| Cash from Financing | 137.37% | ||||
| Foreign Exchange rate Adjustments | -- | ||||
| Miscellaneous Cash Flow Adjustments | -- | ||||
| Net Change in Cash | -- | ||||